1. A scoping review characterizing "Choosing Wisely®" recommendations for breast cancer management

   • Hely Shah
   • Julian Surujballi
   • Mark Clemons

   Review 06 November 2020 Pages: 533 - 547

   

2. The wisdom trial is based on faulty reasoning and has major design and execution problems

   • Daniel B. Kopans

   Review 25 November 2020 Pages: 549 - 556

3. A clinical calculator to predict disease outcomes in women with triple-negative breast cancer

   • Mei-Yin C. Polley
   • Roberto A. Leon-Ferre
   • Matthew P. Goetz

   Review 03 January 2021 Pages: 557 - 566

   

4. Is axillary imaging for invasive lobular carcinoma accurate in determining clinical node staging?

   • Katelyn Schumacher
   • Marc Inciardi
   • Kelsey E. Larson

   Review 03 January 2021 Pages: 567 - 572

   

5. Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution

   • Xiaoxian Li
   • Zhongliang Ma
   • Michael A. Cohen

   Preclinical study 17 October 2020 Pages: 573 - 581

   

6. Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients

   • Vanessa Lattimore
   • Michael T. Parsons
   • Logan Walker

   Preclinical study Open access 28 October 2020 Pages: 583 - 590

7. Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer

   • Andrea Chobrutskiy
   • Boris I. Chobrutskiy
   • George Blanck

   Preclinical study 12 November 2020 Pages: 591 - 600

   

8. The SWI/SNF subunit SMARCD3 regulates cell cycle progression and predicts survival outcome in ER+ breast cancer

   • Romain Tropée
   • Bárbara de la Peña Avalos
   • Eloïse Dray

   Preclinical study 12 November 2020 Pages: 601 - 614

   

9. Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer

   • Khloud A. Elsharawy
   • Maryam Althobiti
   • Emad A. Rakha

   Preclinical study Open access 08 November 2020 Pages: 615 - 627

   

10. Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy

    • Shiwei Liu
    • Shiyan Zeng
    • Purong Zhang

    Preclinical study 09 November 2020 Pages: 629 - 638

    

11. Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA)

    • Katherine Clifton
    • Jingqin Luo
    • Cynthia Ma

    Preclinical study 20 November 2020 Pages: 639 - 646

    

12. Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray

    • R. M. Parks
    • M. A. Albanghali
    • K-L. Cheung

    Preclinical study Open access 23 November 2020 Pages: 647 - 655

    

13. Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?

    • Amparo Garcia-Tejedor
    • Sergi Fernandez-Gonzalez
    • Catalina Falo

    Clinical trial 17 October 2020 Pages: 657 - 666

    

14. The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis

    • Roi Weiser
    • Waqar Haque
    • V. Suzanne Klimberg

    Clinical trial 18 October 2020 Pages: 667 - 676

    

15. To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?

    • S. L. Herbert
    • A. Wöckel
    • BRENDA study group

    Clinical trial Open access 26 October 2020 Pages: 677 - 684

16. Implementing a patient decision aid, a process evaluation of a large-scale pre- and post-implementation trial

    • D. B. Raphael Daniela
    • N. S. Russell
    • L. J. Boersma

    Clinical trial Open access 24 October 2020 Pages: 685 - 695

    

17. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial

    • Manuela Rabaglio
    • Zhuoxin Sun
    • Meredith M. Regan

    Clinical trial 07 November 2020 Pages: 697 - 707

    

18. The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements

    • Chirag Shah
    • April Zambelli-Weiner
    • Jerrod Nelms

    Clinical trial Open access 27 November 2020 Pages: 709 - 740

    

19. Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial

    • Rieneke T. Lugtenberg
    • Stefanie de Groot
    • on behalf of the Dutch Breast Cancer Research Group (BOOG)

    Clinical trial Open access 11 November 2020 Pages: 741 - 758

    

20. Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

    • Jasgit C. Sachdev
    • Pamela Munster
    • Carey Anders

    Clinical trial Open access 17 November 2020 Pages: 759 - 771

    

21. Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study

    • Yin-Che Lu
    • Da-Wei Huang
    • Yi-Jiun Pan

    Epidemiology 16 October 2020 Pages: 773 - 783

    

22. Gene expression of adipokines and adipokine receptors in the tumor microenvironment: associations of lower expression with more aggressive breast tumor features

    • Adana A. M. Llanos
    • Song Yao
    • Kitaw Demissie

    Epidemiology 16 October 2020 Pages: 785 - 798

    

23. Breast cancer risk in patients with polycystic ovary syndrome: a Mendelian randomization analysis

    • Yaokai Wen
    • Xiangrong Wu
    • Wenhua Liang

    Epidemiology 31 October 2020 Pages: 799 - 806

24. A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer

    • Christine Brezden-Masley
    • Kelly E. Fathers
    • Katarzyna J. Jerzak

    Epidemiology Open access 22 October 2020 Pages: 807 - 815

    

25. Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer

    • Gwen M. H. E. Dackus
    • Katarzyna Jóźwiak
    • Sabine C. Linn

    Epidemiology Open access 28 October 2020 Pages: 817 - 830

    

26. Inflammation markers on benign breast biopsy are associated with risk of invasive breast cancer in African American women

    • Asra N. Shaik
    • Katrin Kiavash
    • Michele L. Cote

    Epidemiology 28 October 2020 Pages: 831 - 839

    

27. Racial disparities in survival outcomes among breast cancer patients by molecular subtypes

    • Fangyuan Zhao
    • Brenda Copley
    • Dezheng Huo

    Epidemiology 27 October 2020 Pages: 841 - 849

    

28. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients

    • Renan Gomes
    • Pricila da Silva Spinola
    • Miguel Angelo Martins Moreira

    Epidemiology 30 October 2020 Pages: 851 - 861

29. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function

    • Katia Khoury
    • Filipa Lynce
    • Sandra M. Swain

    Brief report 05 January 2021 Pages: 863 - 868

    

30. The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer

    • Ciyu Yang
    • Angela G. Arnold
    • Liying Zhang

    Brief Report 16 January 2021 Pages: 869 - 877

    

31. New anti-HER2 agents for brain metastasis: histology-agnostic weapons?

    • Paolo Tarantino
    • Aleix Prat
    • Giuseppe Curigliano

    Letter to the Editor 30 October 2020 Pages: 879 - 881

32. Letter to the editor regarding the article “Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer”

    • Xishan Chen
    • Kangwen Guo
    • Jiong Lin

    Letter to the Editor 02 November 2020 Pages: 883 - 883

33. Re: Naoum et al., Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy

    • Sadaf Alipour

    Letter to the Editor 28 October 2020 Pages: 885 - 886

34. Implant-based breast reconstruction: re-analysis of the odds ratio for skin flap necrosis

    • Andrea Messori
    • Laura Bartoli
    • Elisa Ferracane

    Letter to the Editor 22 November 2020 Pages: 887 - 887

35. Correction to: Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen

    • C. Louwrens Braal
    • Koen G. A. M. Hussaarts
    • Ron H. J. Mathijssen

    Correction 23 November 2020 Pages: 889 - 889

36. Correction to: Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations

    • Matthew S. Katz
    • Linda McCall
    • Armando E. Giuliano

    Correction 07 December 2020 Pages: 891 - 891